PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-3.16%
Negative revenue growth while MRVL stands at 7.22%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-4.91%
Negative gross profit growth while MRVL is at 7.08%. Joel Greenblatt would examine cost competitiveness or demand decline.
133.15%
EBIT growth above 1.5x MRVL's 34.18%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
184.17%
Operating income growth above 1.5x MRVL's 34.18%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
37.12%
Net income growth above 1.5x MRVL's 17.13%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
39.13%
EPS growth above 1.5x MRVL's 14.29%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
39.13%
Diluted EPS growth above 1.5x MRVL's 23.08%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.54%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.09%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.74%
Dividend reduction while MRVL stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-66.82%
Negative OCF growth while MRVL is at 187.52%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-72.09%
Negative FCF growth while MRVL is at 362.59%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
98.72%
10Y revenue/share CAGR under 50% of MRVL's 556.40%. Michael Burry would suspect a lasting competitive disadvantage.
5.70%
5Y revenue/share CAGR under 50% of MRVL's 27.00%. Michael Burry would suspect a significant competitive gap or product weakness.
0.26%
3Y revenue/share CAGR under 50% of MRVL's 62.90%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
177.32%
10Y OCF/share CAGR under 50% of MRVL's 1547.43%. Michael Burry would worry about a persistent underperformance in cash creation.
-32.68%
Negative 5Y OCF/share CAGR while MRVL is at 271.41%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.52%
Negative 3Y OCF/share CAGR while MRVL stands at 46.62%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
367.16%
Similar net income/share CAGR to MRVL's 348.90%. Walter Schloss would see parallel tailwinds or expansions for both firms.
-34.45%
Negative 5Y net income/share CAGR while MRVL is 281.25%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-38.72%
Negative 3Y CAGR while MRVL is 190.48%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
54.13%
10Y equity/share CAGR at 50-75% of MRVL's 103.55%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
33.19%
5Y equity/share CAGR at 50-75% of MRVL's 54.76%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
24.41%
3Y equity/share CAGR at 50-75% of MRVL's 40.18%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
846.73%
Dividend/share CAGR of 846.73% while MRVL is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
109.10%
Dividend/share CAGR of 109.10% while MRVL is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
73.43%
3Y dividend/share CAGR of 73.43% while MRVL is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
8.37%
AR growth well above MRVL's 2.48%. Michael Burry fears inflated revenue or higher default risk in the near future.
-3.24%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-1.81%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
0.46%
Positive BV/share change while MRVL is negative. John Neff sees a clear edge over a competitor losing equity.
-0.05%
We’re deleveraging while MRVL stands at 0.00%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-1.41%
Our R&D shrinks while MRVL invests at 0.27%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
6.74%
SG&A growth well above MRVL's 3.45%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.